Table 5.
Results of second-line treatment of cGvHD with ECP
| Author | Patients, n | CR/PR skin, % | CR/PR liver, % | CR/PR oral, % | ORR, % |
Corticosteroid sparing | OS |
|---|---|---|---|---|---|---|---|
| Greinix et al. [61] | 15 | 100 | 90 | 100 | 93 | Yes | 14/15 (93) |
| Salvaneschi et al. [47] | 14 | 83 | 67 | 67 | 64 | Yes | 11/14 (79) |
| Seaton et al. [62] | 28 | 48 | 32 | 21 | 36 | No | 24/28 (86) |
| Apisarnthanarax et al. [63] | 32 | 59 | NA | NA | 56 | Yes | 19/32 (59) |
| Foss et al. [33] | 25 | 64 | 0 | 46 | 64 | Yes | 15/25 (60) |
| Rubegni et al. [64] | 32 | 81 | 77 | 92 | 69 | NA | NA |
| Greinix [65] | 47 | 93 | 84 | 95 | 83 | Yes | 42/47 (89) |
| Couriel et al. [66] | 71 | 57 | 71 | 78 | 61 | Yes | 13/71 (18) |
| Kanold et al. [53] | 15 | 75 | 82 | 86 | 73 | No | 10/15 (67) |
| Perseghin et al. [67] | 25 | 80 | 67 | 78 | 80 | NA | 19/25 (76) |
| Flowers et al. [34] | 48 | 40 | 29 | 53 | Yes | 47/48 (98) | |
| Dignan et al. [68] | 69 | 92 | NA | 91 | 79 | Yes | 50/69 (72) |
| Greinix et al. [35] | 29 | 31 | 50 | 70 | 31 | Yes | 29/29 (100) |
| Del Fante et al. [69] | 88 | NA | NA | NA | NA | NA | NA |
| Hautmann et al. [70] | 32 | 59 | 100 | 60 | 44 | No | 21/32 (66) |
| Malagola et al. [58] | 49 | 15/45 (33) CR for all manifestations | |||||
| Cid et al. [60] | 26 | 77 | 61 |